The company would thus hit turnover of RON430-450 million in the following years, in line with ZF calculations, given that Biofarm generated RON218 million turnover in 2020.
Biofarm has budgeted RON47.4 million investments for 2021.
The company ended the first nine months of 2021 with RON179 million turnover, up 16% from the year-earlier period, and profit worth RON54.8 million, 20% higher than in January-September 2020.
Catalin Vicol specified in 2022 there would be a series of newly launched brands for illnesses for which there’s market demand.
Biofarm has an over 200 product portfolio and ranks fifth among the biggest drug producers in Romania.
(English version by Catalina Apostoiu)